top of page
Home
Calvine Healthcare
Calvine Sustainables
Equity Research
Basilea
Blog
Contact
Use tab to navigate through the menu items.
All Posts
Search
Brian White
Jan 11, 2022
Diurnal business update - much to look forward to
Brian White
Jan 10, 2022
Basilea - 2021 trading update provides financial reassurance
Brian White
Jan 7, 2022
Basilea - Cresemba milestone provides a strong start to 2022
Brian White
Dec 21, 2021
Basilea - Cresemba's China approval
Brian White
Dec 17, 2021
Basilea - A burgeoning oncology pipeline
Andrew Keith
Dec 14, 2021
Diurnal Group - Efmody 2022
Brian White
Dec 8, 2021
Basilea - Cresemba's momentum continues
Andrew Keith
Nov 19, 2021
Basilea - Can derazantinib be class-leading?
Brian White
Nov 16, 2021
Basilea - Oncology commitment
Brian White
Oct 11, 2021
Diurnal Group - making testosterone replacement therapy more convenient
Brian White
Oct 11, 2021
Basilea - Further data supports derazantinib's potential in gastric cancer
Andrew Keith
Sep 30, 2021
Diurnal Group - Smart Delivery
Brian White
Sep 30, 2021
Basilea - Cresemba moving towards approval in Japan
Brian White
Sep 17, 2021
Basilea - Derazantinib ESMO data deliver further support
Brian White
Sep 14, 2021
Diurnal Group - Full year results
Andrew Keith
Sep 1, 2021
Diurnal Group - Positive Efmody update
Brian White
Sep 1, 2021
Basilea - Firing on all fronts
Brian White
Aug 17, 2021
Basilea - A period of strong financial and pipeline performance
Andrew Keith
Aug 9, 2021
Diurnal Group - Efmody's commercialisation
Andrew Keith
Jul 29, 2021
Basilea - FDA orphan designation for lisavanbulin
bottom of page
